Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2011-5-3
pubmed:abstractText
We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1465-3621
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
41
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
617-23
pubmed:meshHeading
pubmed-meshheading:21310730-Adult, pubmed-meshheading:21310730-Aged, pubmed-meshheading:21310730-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21310730-Asian Continental Ancestry Group, pubmed-meshheading:21310730-Camptothecin, pubmed-meshheading:21310730-Colorectal Neoplasms, pubmed-meshheading:21310730-Diarrhea, pubmed-meshheading:21310730-Feasibility Studies, pubmed-meshheading:21310730-Female, pubmed-meshheading:21310730-Fluorouracil, pubmed-meshheading:21310730-Genotype, pubmed-meshheading:21310730-Glucuronosyltransferase, pubmed-meshheading:21310730-Humans, pubmed-meshheading:21310730-Kaplan-Meier Estimate, pubmed-meshheading:21310730-Leucovorin, pubmed-meshheading:21310730-Middle Aged, pubmed-meshheading:21310730-Neoplasm Staging, pubmed-meshheading:21310730-Neutropenia, pubmed-meshheading:21310730-Organoplatinum Compounds, pubmed-meshheading:21310730-Retrospective Studies, pubmed-meshheading:21310730-Thrombocytopenia, pubmed-meshheading:21310730-Treatment Outcome
pubmed:year
2011
pubmed:articleTitle
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
pubmed:affiliation
Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't